vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and ENCORE CAPITAL GROUP INC (ECPG). Click either name above to swap in a different company.
ENCORE CAPITAL GROUP INC is the larger business by last-quarter revenue ($473.6M vs $247.1M, roughly 1.9× ANI PHARMACEUTICALS INC). ENCORE CAPITAL GROUP INC runs the higher net margin — 16.2% vs 11.1%, a 5.1% gap on every dollar of revenue. On growth, ENCORE CAPITAL GROUP INC posted the faster year-over-year revenue change (78.3% vs 29.6%). ENCORE CAPITAL GROUP INC produced more free cash flow last quarter ($126.9M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 20.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Encore Capital Group, Inc. is a publicly traded debt buyer based in the United States. The company is headquartered in San Diego, and operates throughout the United States. The firm is a publicly traded NASDAQ Global Select company (ECPG), a component stock of the Russell 2000, the S&P SmallCap 600, and the Wilshire 4500.
ANIP vs ECPG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $473.6M |
| Net Profit | $27.5M | $76.7M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 36.6% |
| Net Margin | 11.1% | 16.2% |
| Revenue YoY | 29.6% | 78.3% |
| Net Profit YoY | 367.5% | — |
| EPS (diluted) | $1.14 | $3.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $473.6M | ||
| Q3 25 | $227.8M | $460.4M | ||
| Q2 25 | $211.4M | $442.1M | ||
| Q1 25 | $197.1M | $392.8M | ||
| Q4 24 | $190.6M | $265.6M | ||
| Q3 24 | $148.3M | $367.1M | ||
| Q2 24 | $138.0M | $355.3M | ||
| Q1 24 | $137.4M | $328.4M |
| Q4 25 | $27.5M | $76.7M | ||
| Q3 25 | $26.6M | $74.7M | ||
| Q2 25 | $8.5M | $58.7M | ||
| Q1 25 | $15.7M | $46.8M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $30.6M | ||
| Q2 24 | $-2.3M | $32.2M | ||
| Q1 24 | $18.2M | $23.2M |
| Q4 25 | 14.1% | 36.6% | ||
| Q3 25 | 15.9% | 37.6% | ||
| Q2 25 | 6.6% | 34.1% | ||
| Q1 25 | 13.3% | 32.9% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -13.8% | 28.9% | ||
| Q2 24 | 3.7% | 28.7% | ||
| Q1 24 | 14.8% | 25.5% |
| Q4 25 | 11.1% | 16.2% | ||
| Q3 25 | 11.7% | 16.2% | ||
| Q2 25 | 4.0% | 13.3% | ||
| Q1 25 | 8.0% | 11.9% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 8.3% | ||
| Q2 24 | -1.7% | 9.1% | ||
| Q1 24 | 13.2% | 7.1% |
| Q4 25 | $1.14 | $3.32 | ||
| Q3 25 | $1.13 | $3.17 | ||
| Q2 25 | $0.36 | $2.49 | ||
| Q1 25 | $0.69 | $1.93 | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | $1.26 | ||
| Q2 24 | $-0.14 | $1.34 | ||
| Q1 24 | $0.82 | $0.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $156.8M |
| Total DebtLower is stronger | — | $4.0B |
| Stockholders' EquityBook value | $540.7M | $976.8M |
| Total Assets | $1.4B | $5.3B |
| Debt / EquityLower = less leverage | — | 4.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $156.8M | ||
| Q3 25 | $262.6M | $172.5M | ||
| Q2 25 | $217.8M | $172.9M | ||
| Q1 25 | $149.8M | $187.1M | ||
| Q4 24 | $144.9M | $199.9M | ||
| Q3 24 | $145.0M | $247.4M | ||
| Q2 24 | $240.1M | $250.6M | ||
| Q1 24 | $228.6M | $173.0M |
| Q4 25 | — | $4.0B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $3.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $976.8M | ||
| Q3 25 | $505.8M | $952.9M | ||
| Q2 25 | $436.8M | $896.0M | ||
| Q1 25 | $418.6M | $819.1M | ||
| Q4 24 | $403.7M | $767.3M | ||
| Q3 24 | $405.9M | $1.0B | ||
| Q2 24 | $455.8M | $988.1M | ||
| Q1 24 | $452.0M | $953.9M |
| Q4 25 | $1.4B | $5.3B | ||
| Q3 25 | $1.4B | $5.3B | ||
| Q2 25 | $1.3B | $5.2B | ||
| Q1 25 | $1.3B | $5.0B | ||
| Q4 24 | $1.3B | $4.8B | ||
| Q3 24 | $1.3B | $5.0B | ||
| Q2 24 | $920.8M | $4.8B | ||
| Q1 24 | $914.5M | $4.7B |
| Q4 25 | — | 4.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.83× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $153.2M |
| Free Cash FlowOCF − Capex | $29.1M | $126.9M |
| FCF MarginFCF / Revenue | 11.8% | 26.8% |
| Capex IntensityCapex / Revenue | 0.5% | 5.5% |
| Cash ConversionOCF / Net Profit | 1.10× | 2.00× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $244.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $153.2M | ||
| Q3 25 | $44.1M | $81.6M | ||
| Q2 25 | $75.8M | $9.5M | ||
| Q1 25 | $35.0M | $45.3M | ||
| Q4 24 | $15.9M | $156.2M | ||
| Q3 24 | $12.5M | $45.9M | ||
| Q2 24 | $17.4M | $35.7M | ||
| Q1 24 | $18.3M | $51.0M |
| Q4 25 | $29.1M | $126.9M | ||
| Q3 25 | $38.0M | $75.6M | ||
| Q2 25 | $71.8M | $3.2M | ||
| Q1 25 | $32.5M | $38.3M | ||
| Q4 24 | $13.5M | $127.2M | ||
| Q3 24 | $7.7M | $39.7M | ||
| Q2 24 | $13.0M | $28.3M | ||
| Q1 24 | $13.7M | $44.1M |
| Q4 25 | 11.8% | 26.8% | ||
| Q3 25 | 16.7% | 16.4% | ||
| Q2 25 | 34.0% | 0.7% | ||
| Q1 25 | 16.5% | 9.7% | ||
| Q4 24 | 7.1% | 47.9% | ||
| Q3 24 | 5.2% | 10.8% | ||
| Q2 24 | 9.4% | 8.0% | ||
| Q1 24 | 10.0% | 13.4% |
| Q4 25 | 0.5% | 5.5% | ||
| Q3 25 | 2.7% | 1.3% | ||
| Q2 25 | 1.9% | 1.4% | ||
| Q1 25 | 1.3% | 1.8% | ||
| Q4 24 | 1.3% | 10.9% | ||
| Q3 24 | 3.2% | 1.7% | ||
| Q2 24 | 3.2% | 2.1% | ||
| Q1 24 | 3.3% | 2.1% |
| Q4 25 | 1.10× | 2.00× | ||
| Q3 25 | 1.66× | 1.09× | ||
| Q2 25 | 8.87× | 0.16× | ||
| Q1 25 | 2.23× | 0.97× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.50× | ||
| Q2 24 | — | 1.11× | ||
| Q1 24 | 1.00× | 2.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ECPG
Segment breakdown not available.
